230 related articles for article (PubMed ID: 1576621)
21. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
Bourgault AM; Lamothe F
J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF.
Treviño M; Areses P; Peñalver MD; Cortizo S; Pardo F; del Molino ML; García-Riestra C; Hernández M; Llovo J; Regueiro BJ
Anaerobe; 2012 Feb; 18(1):37-43. PubMed ID: 22261518
[TBL] [Abstract][Full Text] [Related]
23. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility of anaerobic bacteria to five antimicrobial agents and demonstration of resistance of Bacteroides fragilis to clindamycin.
Sofianou D; Douboyas J; Papapanagiotou J; Paradelis AG
Methods Find Exp Clin Pharmacol; 1982; 4(3):173-7. PubMed ID: 7121128
[TBL] [Abstract][Full Text] [Related]
25. [Evolution of the sensitivity of Bacteroides group fragilis at the Sevilla University Hospital (1983-1987)].
Borobio MV; Domínguez MC; Pallares JA; Perea EJ
Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):214-8. PubMed ID: 1863620
[TBL] [Abstract][Full Text] [Related]
26. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.
Snydman DR; Jacobus NV; McDermott LA; Golan Y; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rosenblatt J; Venezia R; Gorbach SL; Queenan AM; Hecht DW
Anaerobe; 2011 Aug; 17(4):147-51. PubMed ID: 21664469
[TBL] [Abstract][Full Text] [Related]
27. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
Aldridge KE
Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
[TBL] [Abstract][Full Text] [Related]
28. In vitro activities of 36 antimicrobial agents against clinically isolated Bacteroides fragilis.
Teng LJ; Ho SW; Chang SC; Luh KT; Hsieh WC
J Formos Med Assoc; 1991 Aug; 90(8):796-9. PubMed ID: 1683376
[TBL] [Abstract][Full Text] [Related]
29. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
Aldridge KE; Gelfand M; Reller LB; Ayers LW; Pierson CL; Schoenknecht F; Tilton RC; Wilkins J; Henderberg A; Schiro DD
Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
[TBL] [Abstract][Full Text] [Related]
30. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility trending of blood isolates of the Bacteroides fragilis group over a 12-year period to clindamycin, ampicillin-sulbactam, cefoxitin, imipenem, and metronidazole.
Aldridge KE; Sanders CV
Anaerobe; 2002 Dec; 8(6):301-5. PubMed ID: 16887673
[TBL] [Abstract][Full Text] [Related]
32. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.
Snydman DR; Jacobus NV; McDermott LA; Supran S; Cuchural GJ; Finegold S; Harrell L; Hecht DW; Iannini P; Jenkins S; Pierson C; Rihs J; Gorbach SL
Antimicrob Agents Chemother; 1999 Oct; 43(10):2417-22. PubMed ID: 10508018
[TBL] [Abstract][Full Text] [Related]
33. [The sensitivity of anaerobic bacteria to chemotherapeutic agents (Zurich, 1991)].
Wüst J; Hardegger U
Schweiz Rundsch Med Prax; 1991 Dec; 80(52):1474-80. PubMed ID: 1815309
[TBL] [Abstract][Full Text] [Related]
34. Emergence of antibiotic resistant strains of Bacteroides fragilis.
Scher KS
Surg Gynecol Obstet; 1988 Sep; 167(3):175-9. PubMed ID: 3413646
[TBL] [Abstract][Full Text] [Related]
35. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
Jacobs MR; Spangler SK; Appelbaum PC
J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
[TBL] [Abstract][Full Text] [Related]
36. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
Betriu C; Cabronero C; Gomez M; Picazo JJ
Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
[TBL] [Abstract][Full Text] [Related]
37. Clindamycin resistance in anaerobic bacteria.
Tally FP; Cuchural GJ; Bieluch VM; Jacobus NV; Malamy MH
Scand J Infect Dis Suppl; 1984; 43():34-43. PubMed ID: 6598519
[TBL] [Abstract][Full Text] [Related]
38. Resistance to beta-lactam antibiotics and beta-lactamase production of Bacteroides, Porphyromonas and Prevotella strains.
Nagy E; Szóke I; Gacs M; Csiszár K
Acta Microbiol Immunol Hung; 1995; 42(3):287-99. PubMed ID: 8548202
[TBL] [Abstract][Full Text] [Related]
39. In vitro anaerobic data on ticarcillin/clavulanate. A review of an ongoing survey.
Sanders CV; Aldridge KE
J Reprod Med; 1990 Mar; 35(3 Suppl):313-6. PubMed ID: 2319513
[TBL] [Abstract][Full Text] [Related]
40. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
